Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 13 12 2023
accepted: 15 08 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 13 9 2024
Statut: epublish

Résumé

China's National Essential Medicines Policy (NEMP) has been implemented for over 15 years; yet empirical evidence on its long-term impacts is lacking, particularly in remote and rural regions. This study aims to assess the short-and long-term effects of NEMP on the drug availability, price, and usage in a deprived rural county in southwestern China. A quasi-experimental design was employed, featuring a single-group pre-and-post comparison. We gathered 74,436 procurement records spanning from 2009 to 2016 from the drug warehouses of local medical institutions. Pharmaceutical data were analyzed quarterly, considering various policy and therapeutic attributes. Fisher's Drug Price Index (DPI-F) was calibrated for the retail and wholesale prices of a consistent collection of 405 medications. We conducted interrupted time-series analysis to examine the immediate and enduring impacts of NEMP's initial (commencing in January 2011) and second (starting from December 2015) stages. After initiation of NEMP, the number of available essential medicines surged by 115 but subsequently faced a steady quarterly decline (-9.1) in township healthcare centers (THCs, primary care). Conversely, county hospitals (secondary care) initially saw a reduction of 40 in drug availability but later exhibited a steady increase (+4.2 per quarter) up to the second-stage NEMP. Regarding price, THCs encountered abrupt (-26.1%/-15.9% in retail/wholesale price) and sustained (-0.2%/-0.3% per quarter) price drops after NEMP. The immediate price change after NEMP in county hospitals were milder but significant in non-essential medicines, and long-term declines were also observed in all drugs. As for total sales, a significant long-term disparity emerged between THCs (+0.9% per quarter) and county hospitals (+3.3% per quarter). Following the second-stage NEMP, retail prices in county hospitals further decreased, although wholesale prices did not; however, following price upward trends were observed in both THCs and county hospitals. Lastly, the influences of NEMP varied across different therapeutical categories of medicines. NEMP has successfully regulated drug prices in primary and secondary healthcare facilities in remote and rural areas, both short-term and long-term. However, a remarkable disparity in medicine availability and utilization was observed between different levels of facilities over time. Continuous monitoring is essential, with increased attention needed on the uneven impacts of the policy on diverse drugs, facilities, regions, and demographics.

Sections du résumé

Background UNASSIGNED
China's National Essential Medicines Policy (NEMP) has been implemented for over 15 years; yet empirical evidence on its long-term impacts is lacking, particularly in remote and rural regions. This study aims to assess the short-and long-term effects of NEMP on the drug availability, price, and usage in a deprived rural county in southwestern China.
Methods UNASSIGNED
A quasi-experimental design was employed, featuring a single-group pre-and-post comparison. We gathered 74,436 procurement records spanning from 2009 to 2016 from the drug warehouses of local medical institutions. Pharmaceutical data were analyzed quarterly, considering various policy and therapeutic attributes. Fisher's Drug Price Index (DPI-F) was calibrated for the retail and wholesale prices of a consistent collection of 405 medications. We conducted interrupted time-series analysis to examine the immediate and enduring impacts of NEMP's initial (commencing in January 2011) and second (starting from December 2015) stages.
Results UNASSIGNED
After initiation of NEMP, the number of available essential medicines surged by 115 but subsequently faced a steady quarterly decline (-9.1) in township healthcare centers (THCs, primary care). Conversely, county hospitals (secondary care) initially saw a reduction of 40 in drug availability but later exhibited a steady increase (+4.2 per quarter) up to the second-stage NEMP. Regarding price, THCs encountered abrupt (-26.1%/-15.9% in retail/wholesale price) and sustained (-0.2%/-0.3% per quarter) price drops after NEMP. The immediate price change after NEMP in county hospitals were milder but significant in non-essential medicines, and long-term declines were also observed in all drugs. As for total sales, a significant long-term disparity emerged between THCs (+0.9% per quarter) and county hospitals (+3.3% per quarter). Following the second-stage NEMP, retail prices in county hospitals further decreased, although wholesale prices did not; however, following price upward trends were observed in both THCs and county hospitals. Lastly, the influences of NEMP varied across different therapeutical categories of medicines.
Conclusion UNASSIGNED
NEMP has successfully regulated drug prices in primary and secondary healthcare facilities in remote and rural areas, both short-term and long-term. However, a remarkable disparity in medicine availability and utilization was observed between different levels of facilities over time. Continuous monitoring is essential, with increased attention needed on the uneven impacts of the policy on diverse drugs, facilities, regions, and demographics.

Identifiants

pubmed: 39267638
doi: 10.3389/fpubh.2024.1355239
pmc: PMC11390679
doi:

Substances chimiques

Drugs, Essential 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1355239

Informations de copyright

Copyright © 2024 Xiong, Huo, Zhou, Bai, He, Zhou, Jia, Quan and Luo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Health Plann Manage. 2020 Mar;35(2):545-557
pubmed: 31736154
PLOS Digit Health. 2023 Apr 25;2(4):e0000238
pubmed: 37098005
Int J Equity Health. 2018 Oct 19;17(1):158
pubmed: 30340587
Zhonghua Er Ke Za Zhi. 2020 Apr 2;58(4):301-307
pubmed: 32234137
Int J Health Policy Manag. 2021 Jan 01;10(1):14-21
pubmed: 32610744
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
J Clin Pharm Ther. 2002 Aug;27(4):299-309
pubmed: 12174032
J Int Soc Prev Community Dent. 2017 Jul-Aug;7(4):147-160
pubmed: 28852629
Lancet. 2017 Jan 28;389(10067):403-476
pubmed: 27832874
Front Pharmacol. 2022 Feb 16;13:828152
pubmed: 35250577
Lancet. 2019 Sep 28;394(10204):1192-1204
pubmed: 31571602
PLoS One. 2015 Mar 19;10(3):e0121630
pubmed: 25790443
Front Public Health. 2022 Apr 12;10:860471
pubmed: 35493374
Inquiry. 2018 Jan-Dec;55:46958018787057
pubmed: 30239238
Front Pharmacol. 2020 Nov 26;11:602421
pubmed: 33381042
Health Econ. 2008 Feb;17(2):149-65
pubmed: 17880024
Lancet Glob Health. 2013 Oct;1(4):e227-37
pubmed: 25104348
BMC Health Serv Res. 2015 Aug 27;15:345
pubmed: 26310243
Int J Equity Health. 2015 Jul 30;14:58
pubmed: 26219841
Soc Sci Med. 2015 Nov;145:201-8
pubmed: 26360408
Front Public Health. 2023 Apr 25;11:1149838
pubmed: 37181691
Front Pharmacol. 2020 Sep 08;11:1231
pubmed: 33013357
Lancet. 2003 May 17;361(9370):1723-9
pubmed: 12767751
J Pharm Policy Pract. 2022 Oct 22;15(1):68
pubmed: 36273222
BMC Public Health. 2021 Oct 19;21(1):1883
pubmed: 34663282
Front Pharmacol. 2020 Aug 14;11:1123
pubmed: 32922285
Health Soc Care Community. 2018 Jul;26(4):495-506
pubmed: 29479777
Int J Epidemiol. 2018 Dec 1;47(6):2082-2093
pubmed: 29982445
Int J Antimicrob Agents. 2016 Oct;48(4):409-14
pubmed: 27502753
Front Pharmacol. 2023 May 05;14:1153972
pubmed: 37214447
BMC Health Serv Res. 2019 Dec 19;19(1):980
pubmed: 31856821
PLoS One. 2018 Aug 2;13(8):e0201582
pubmed: 30070998
Bull World Health Organ. 2013 Mar 1;91(3):184-94
pubmed: 23476091
BMC Health Serv Res. 2014 Oct 25;14:507
pubmed: 25344413
J Pharm Policy Pract. 2014 Sep 17;7(1):12
pubmed: 25317336
J Med Econ. 2013;16(2):289-94
pubmed: 23215958
Int J Environ Res Public Health. 2020 Dec 15;17(24):
pubmed: 33334027
J Pharm Policy Pract. 2021 Mar 4;14(1):28
pubmed: 33663583
BMC Health Serv Res. 2017 Nov 13;17(1):723
pubmed: 29132361
Soc Sci Med. 2013 Sep;93:220-8
pubmed: 23103350

Auteurs

Xuechen Xiong (X)

School of Public Health, Fudan University, Shanghai, China.
School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Zhaohua Huo (Z)

Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Shuai Zhou (S)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Ge Bai (G)

School of Public Health, Fudan University, Shanghai, China.

Shiying He (S)

School of Public Health, Fudan University, Shanghai, China.

Yinan Zhou (Y)

School of Public Health, Fudan University, Shanghai, China.

Jing Jia (J)

JC School of Public Health, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Jianchao Quan (J)

School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Li Luo (L)

School of Public Health, Fudan University, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH